References
- UNAIDS/WHO. AIDS Epidemic Update: December, UNAIDS/WHO (2006).
- Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl Acad. Sci. USA96, 10958–10961 (1999).
- Anastassopoulou CG, Kostrikis LG. Global genetic variation of HIV-1 infection. Curr. HIV Res.4, 365–373 (2006).
- Villinger F, Brar SS, Brice GT et al. Immune and hematopoietic parameters in HIV-1-infected chimpanzees during clinical progression toward AIDS. J. Med. Primatol.26, 11–18 (1997).
- Hirbod T, Broliden K. Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J. Intern. Med.262, 44–58 (2007).
- Johnston MI, Fauci AS. An HIV vaccine – evolving concepts. N. Engl. J. Med.356, 2073–2081 (2007).
- Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis.191, 654–665 (2005).
- Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis.194, 1661–1671 (2006).
- McMichael AJ. HIV. The immune response. Curr. Opin. Immunol.8, 537–539 (1996).
- McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. Nature410, 980–987 (2001).
- Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science279, 2103–2106 (1998).
- Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science292, 69–74 (2001).
- Barouch DH, Santra S, Schmitz JE et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science290, 486–492 (2000).
- Barouch DH, Kunstman J, Kuroda MJ et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature415, 335–339 (2002).
- Feeney ME, Tang Y, Roosevelt KA et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J. Virol.78, 8927–8930 (2004).
- Goulder PJ, Phillips RE, Colbert RA et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med.3, 212–217 (1997).
- Crooks ET, Moore PL, Franti M et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology366(2), 245–262 (2007).
- Dey AK, David KB, Klasse PJ, Moore JP. Specific amino acids in the N-terminus of the gp41 ectodomain contribute to the stabilization of a soluble, cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1. Virology360, 199–208 (2007).
- Yuan W, Bazick J, Sodroski J. Characterization of the multiple conformational states of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J. Virol.80, 6725–6737 (2006).
- Baba TW, Liska V, Hofmann-Lehmann R et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection. Nat. Med.6, 200–206 (2000).
- Emini EA, Schleif WA, Nunberg JH et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature355, 728–730 (1992).
- Parren PW, Marx PA, Hessell AJ et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol.75, 8340–8347 (2001).
- Baeten JM, Overbaugh J. Measuring the infectiousness of persons with HIV-1: opportunities for preventing sexual HIV-1 transmission. Curr. HIV Res.1, 69–86 (2003).
- Chan DJ. Fatal attraction: sex, sexually transmitted infections and HIV-1. Int. J. STD AIDS17, 643–651 (2006).